Role of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Up… (NCT03318094) | Clinical Trial Compass
Active — Not RecruitingPhase 1
Role of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in Obesity
United States36 participantsStarted 2017-10-24
Plain-language summary
The purpose of this study is to better understand the contribution of sympathetic vasoconstriction to impaired insulin-mediated vasodilation and subsequently insulin-mediated glucose uptake. The investigators will test the hypothesis that removal of sympathetic vasoconstriction can result in improvement in insulin-mediated vasodilation and subsequently sensitivity to insulin-mediated glucose uptake.
Who can participate
Age range18 Years – 60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Males and females of all races between 18 and 60 years of age.
* Obesity defined as body mass index between 30-40 kg/m2
* Insulin resistance defined as homeostasis model assessment 2 insulin resistance (HOMA2-IR) score \>1.6 (never diagnosed or treated type 2 diabetic), or being a well-controlled type 2 diabetic on metformin only.
* Able and willing to provide informed consent
Exclusion Criteria:
* Pregnancy or breastfeeding
* Current smokers or history of heavy smoking (\>2 packs/day)
* History of alcohol or drug abuse
* Morbid obesity (BMI \> 40 kg/m2)
* Previous allergic reaction to study medications
* Evidence of type I diabetes.
* Cardiovascular disease other than hypertension such as myocardial infarction within 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, second or third-degree heart block, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy
* History of serious cerebrovascular disease such as cerebral hemorrhage, stroke, or transient ischemic attack
* History or presence of immunological or hematological disorders
* Impaired hepatic function \[aspartate amino transaminase (AST) and/or alanine amino transaminase (ALT) \> 2.0 x upper limit of normal range\]
* Impaired renal function (serum creatinine \>1.5 mg/dl)
* Moderate to severe anemia (hemoglobin \<11 g/dl)
* Treatment with serotonin-norep…
What they're measuring
1
Contrast Enhanced-Ultrasonography (CEU)
Timeframe: Before clamp and 15 minutes after clamp